![Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin | Scientific Reports Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-023-32426-6/MediaObjects/41598_2023_32426_Fig1_HTML.png)
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin | Scientific Reports
![Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma | Bone Marrow Transplantation Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma | Bone Marrow Transplantation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bmt.1702850/MediaObjects/41409_2001_Article_BF1702850_Fig1_HTML.jpg)
Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma | Bone Marrow Transplantation
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies | Journal of Experimental & Clinical Cancer Research | Full Text Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13046-015-0155-4/MediaObjects/13046_2015_155_Fig1_HTML.gif)
Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies | Journal of Experimental & Clinical Cancer Research | Full Text
![Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table2-1.png)
Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar](https://ai2-s2-public.s3.amazonaws.com/figures/2017-08-08/92e61d19dc92e499c7b7b01818ac923837d9f518/2-Table2-1.png)
PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar
![Patient 1 with a history of IgG kappa multiple myeloma presented with... | Download Scientific Diagram Patient 1 with a history of IgG kappa multiple myeloma presented with... | Download Scientific Diagram](https://www.researchgate.net/publication/31292541/figure/fig1/AS:309933695356934@1450905359416/Patient-1-with-a-history-of-IgG-kappa-multiple-myeloma-presented-with-acute-renal.png)